Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein S deficiency

D Borgel1, S Gandrille, M Aiach

  • 1Unité INSERM 428, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France. borgel@infobiogen.fr

Thrombosis and Haemostasis
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

[Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].

Pathologie-biologie·2015
Same author

A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Platelet dysfunction associated with the novel Trp29Cys thromboxane A₂ receptor variant.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Vascular endothelial growth factor, as compared with placental growth factor, is increased in severe sepsis but not in organ failure.

Journal of thrombosis and haemostasis : JTH·2012
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Protein S (PS) deficiency, a cofactor in the protein C (PC) pathway, increases the risk of recurrent thrombosis. Genetic mutations causing PS deficiency are diverse and impact allele expression, affecting thrombosis risk.

Area of Science:

  • Biochemistry
  • Hematology
  • Genetics

Background:

  • The protein C (PC) pathway, with its cofactor protein S (PS), is a critical natural antithrombotic mechanism.
  • Deficiency in protein S is linked to an increased risk of thrombotic events.

Purpose of the Study:

  • To summarize the clinical implications and molecular heterogeneity of hereditary protein S deficiency.

Main Methods:

  • Literature review of studies on protein S deficiency and thrombosis.
  • Analysis of genetic mutations affecting protein S function and expression.

Main Results:

  • Phenotypic protein S deficiency is associated with recurrent thrombosis in adulthood.
  • Individuals with PS deficiency have approximately a 50% chance of remaining thrombosis-free by age 45.

Related Experiment Videos

  • Hereditary PS deficiencies exhibit significant molecular heterogeneity due to a wide spectrum of mutations.

    • Conclusions:

    • Protein S deficiency represents a significant risk factor for adult-onset recurrent thrombosis.
    • Understanding the molecular basis of PS deficiency is crucial for risk assessment and management.